Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The outcome in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitis has considerably improved with the use of potent immunosuppression. In the most severe cases, mortality remains an important risk despite aggressive intervention. However, for most patients who survive, quality of survival is affected by morbidity due to low-grade disease activity, episodes of relapse, damage from the effects of disease and its treatment, development of associated comorbidity, and the social and psychological problems of chronic disease. A rational approach to management of patients with ANCA-associated vasculitis requires careful measurement of these different facets of disease, so that treatment is appropriate. This article reviews the development of assessment tools used to quantify disease in vasculitis, which have been extensively used in clinical trials and are also appropriate for use in individual patient care.

Original publication

DOI

10.1016/j.rdc.2010.04.001

Type

Journal article

Journal

Rheumatic diseases clinics of North America

Publication Date

08/2010

Volume

36

Pages

587 - 607

Addresses

Department of Rheumatology, Nuffield Orthopaedic Centre, Oxford, OX3 7LD, UK.

Keywords

Humans, Treatment Outcome, Severity of Illness Index, Recovery of Function, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis